SITAGLIPTIN PHOSPHATE AND METFORMIN HYDROCHLORIDE
Pre-Launchmetformin hydrochloride, sitagliptin phosphate
ANDAFILM COATEDTABLET
Lifecycle
Pre-Launch
Data completeness
1/8 — Limited
SITAGLIPTIN PHOSPHATE AND METFORMIN HYDROCHLORIDE (metformin hydrochloride, sitagliptin phosphate) by Inpharmus is 2 diabetes mellitus, lowering both basal and postprandial plasma glucose.
Drug data last refreshed 1mo ago
Mechanism of Action
2 diabetes mellitus, lowering both basal and postprandial plasma glucose. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. With metformin therapy, insulin secretion…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
Inpharmus
Worked on SITAGLIPTIN PHOSPHATE AND METFORMIN HYDROCHLORIDE at Inpharmus? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.